Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pepscan, a Netherlands-based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, has reached a partnering agreement with Immunovo for its therapeutic vaccine portfolio.
Subscribe to our email newsletter
As per the terms of the agreement Pepscan is expected to receive an undisclosed cash payment as well as a minority interest in Immunovo.
Wim Mol, CEO of Pepscan, said: “Pepscan has recently refocused its R&D program on the application of its proprietary CLIPS (Chemical LInkage of Peptides onto Scaffolds) protein mimicry technology for the generation of monoclonal antibodies and therapeutic peptides.
“The agreement with Immunovo allows Pepscan to fully concentrate its resources on a focused execution of its research program. We consider Immunovo as an ideal partner to enhance the value of the therapeutic vaccine portfolio we have developed over the years.”
Joost van Bree, CEO of Immunovo, said: “We are very pleased with the partnership with Pepscan on the therapeutic vaccine portfolio. Pepscan created a rich development pipeline of therapeutic vaccines, of which the most advanced product is in Phase II clinical development.
“We are confident that with our specific expertise we will be able to expedite the development of this portfolio, which also includes a proprietary anti-VEGF-A vaccine that could be useful for the treatment of certain cancers.”